Free Trial

Sangamo Therapeutics (SGMO) News Today

$0.60
-0.01 (-0.87%)
(As of 05:17 PM ET)
Wasatch Advisors LP Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)
Wasatch Advisors LP reduced its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 31.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 12,397,924 shares of the biopharmaceutical company's stock after selling 5,588,857 shares during the q
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Moderate Buy" from Brokerages
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has received a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a bu
Q2 2024 EPS Estimates for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Decreased by HC Wainwright
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for Sangamo Therapeutics in a report issued on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical
HC Wainwright Weighs in on Sangamo Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:SGMO)
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Sangamo Therapeutics in a research report issued to clients and investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will ea
Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a report on Wednesday.
Sangamo Therapeutics (NASDAQ:SGMO) Issues Earnings Results
Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. The business had revenue of $0.48 million during the quarter, compared to analysts' expectations of $8.51 million. During the same period in the previous year, the business earned $0.12 EPS.
Sangamo Therapeutics (SGMO) Scheduled to Post Quarterly Earnings on Thursday
Sangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.
Sangamo Therapeutics Inc.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Hold" by Brokerages
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have received a consensus recommendation of "Hold" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold r
Stock Traders Purchase Large Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO)
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw some unusual options trading activity on Monday. Investors bought 11,259 call options on the stock. This represents an increase of approximately 2,053% compared to the typical volume of 523 call options.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have received a consensus recommendation of "Hold" from the seven ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating an
Sangamo Therapeutics (NASDAQ:SGMO) Share Price Passes Above 200-Day Moving Average of $0.62
Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Crosses Above 200-Day Moving Average of $0.62
Q1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By HC Wainwright
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2024 earnings estimates for shares of Sangamo Therapeutics in a research note issued on Tuesday, March 19th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical co
Sangamo Therapeutics Inc
Sangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $5.00 price target (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday.
Sangamo Therapeutics' (SGMO) Sector Perform Rating Reaffirmed at Royal Bank of Canada
Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research note on Thursday.
Q1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By Wedbush
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Research analysts at Wedbush issued their Q1 2024 EPS estimates for Sangamo Therapeutics in a research note issued to investors on Thursday, March 14th. Wedbush analyst A. Argyrides anticipates that the biopharmaceutical company will post e
SGMO Apr 2024 1.500 put
SGMO Apr 2024 1.500 call
SGMO Apr 2024 3.000 call
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
Sangamo Therapeutics, Inc. (SGMO)
Sangamo Therapeutics (SGMO) Earnings Dates & Reports
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Sees Significant Growth in Short Interest
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 9,980,000 shares, a growth of 9.0% from the January 15th total of 9,160,000 shares. Based on an average trading volume of 1,650,000 shares, the short-interest ratio is currently 6.0 days.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Hold" by Analysts
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has earned an average recommendation of "Hold" from the seven research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three
Sangamo Therapeutics (NASDAQ:SGMO) Rating Reiterated by HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $3.00 target price on shares of Sangamo Therapeutics in a report on Tuesday.
Get Sangamo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (Ad)

Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!

TRY "INVESTING IDEAS" TODAY

SGMO Media Mentions By Week

SGMO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SGMO
News Sentiment

1.89

1.08

Average
Medical
News Sentiment

SGMO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SGMO Articles
This Week

3

2

SGMO Articles
Average Week

Get Sangamo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:SGMO) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners